5/29/2023 0 Comments Bpi sports calculators![]() ![]() LeDoux, NAI's CEO and Chairman of the Board, explained the filing of two new lawsuits by saying that "NAI has made a significant corporate investment in its growing patent portfolio related to CarnoSyn® beta-alanine and, when necessary, will continue to address infringement of its intellectual property using the federal court system. Corporation, d/b/a Integrity Nutraceuticals regarding certain beta-alanine containing products. The two new lawsuits follow NAI's Decemfiling of a patent infringement action alleging infringement of the '381 patent against Woodbolt Distribution, LLC, Vitaquest International, Inc., d/b/a Garden State Nutritionals and F.H.G. NAI also filed a separate lawsuit for infringement of the '381 patent alleging that Image makes, uses, offers for sale and sells nutritional supplements and bundled supplement products containing beta-alanine such as its Alarm™ product. The complaint alleges that BPI infringes the '381 patent by making, using, offering for sale and selling nutritional supplements and bundled supplement products containing beta-alanine such as its 1.M.R.™ product. NAI filed its complaint against BPI in federal court after BPI failed to comply with a cease and desist demand. Patent and Trademark Office and is part of NAI's worldwide portfolio covering CarnoSyn® beta-alanine. 8,067,381 ("the '381 patent"), entitled "Methods and compositions for increasing the anaerobic working capacity in tissues." The '381 patent was issued by the U.S. District Court for the Southern District of Texas, Houston Division, for infringing U.S. ![]() ("NAI") (NASDAQ: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, announced today that on January 20 it instituted two new patent litigations against BPI Sports Holdings, LLC d/b/a BPI Sports, LLC and BPI Sports ("BPI") and Image Sports, LLC d/b/a Image Nutrition LLC ("Image") in the U.S. 24, 2012 /PRNewswire/ - Natural Alternatives International, Inc. ![]()
0 Comments
Leave a Reply. |